Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Neurology, Neurosurgery, and Psychiatry|March 5, 2015
TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic responseCarlos López-Gómez, Begoña Oliver-Martos, María-Jesús Pinto-Medel, et al.
Scientific Reports|August 20, 2017
Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatmentMaría Jesús Pinto-Medel, Begoña Oliver-Martos, Patricia Urbaneja-Romero, et al.
Journal of Neurology|July 9, 2009
HLA class II alleles in patients with multiple sclerosis in the Biscay province (Basque Country, Spain)Oscar Fernández, Alfredo R-Antigüedad, María Jesús Pinto-Medel, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 28, 2015
Cell-specific effects in different immune subsets associated with SOCS1 genotypes in multiple sclerosisAitzkoa Lopez de Lapuente, María Jesús Pinto-Medel, Ianire Astobiza, et al.
Journal of Neuroimmunology|January 21, 2012
The CD4+ T-cell subset lacking expression of the CD28 costimulatory molecule is expanded and shows a higher activation state in multiple sclerosisMaría Jesús Pinto-Medel, Juan Antonio García-León, Begoña Oliver-Martos, et al.
Journal of Clinical Medicine|July 30, 2020
Skin Phototype Could Be a Risk Factor for Multiple SclerosisPatricia Urbaneja, Isaac Hurtado-Guerrero, Miguel Ángel Hernández, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 24, 2010
Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 monthsBegoña Oliver, Oscar Fernández, Teresa Orpez, et al.
Plos One|May 10, 2013
Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patientsCarlos López-Gómez, Almudena Pino-Ángeles, Teresa Órpez-Zafra, et al.
Plos One|August 5, 2011
TRAIL/TRAIL receptor system and susceptibility to multiple sclerosisCarlos López-Gómez, Oscar Fernández, Juan Antonio García-León, et al.
Scientific Reports|August 30, 2020
Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumabMaria Inmaculada Dominguez-Mozo, Silvia Perez-Perez, Luisa María Villar, et al.
Pageof 2